Clinical Trial Update: Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) [Phase 3]

View source ↗

Summary

Phase 3 trial update for Gemtuzumab Ozogamicin in induction and Glasdegib in postremission therapy in acute myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)
• Glasdegib (glasdegib)

Snippet

Sponsor: University Hospital Heidelberg | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: TERMINATED